Virtu Financial LLC Sells 993 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Virtu Financial LLC decreased its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 33.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,002 shares of the biotechnology company’s stock after selling 993 shares during the period. Virtu Financial LLC’s holdings in Ascendis Pharma A/S were worth $252,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vestal Point Capital LP bought a new position in Ascendis Pharma A/S during the 4th quarter valued at approximately $78,719,000. Certuity LLC bought a new position in Ascendis Pharma A/S during the 4th quarter valued at approximately $270,000. Invesco Ltd. raised its position in Ascendis Pharma A/S by 9.3% during the 3rd quarter. Invesco Ltd. now owns 672,126 shares of the biotechnology company’s stock valued at $62,938,000 after purchasing an additional 57,413 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in shares of Ascendis Pharma A/S in the 4th quarter worth approximately $5,779,000. Finally, Seven Eight Capital LP bought a new position in shares of Ascendis Pharma A/S in the 4th quarter worth approximately $2,347,000.

Ascendis Pharma A/S Stock Up 5.1 %

ASND stock opened at $127.85 on Friday. Ascendis Pharma A/S has a twelve month low of $85.08 and a twelve month high of $161.00. The firm has a market cap of $7.44 billion, a PE ratio of -13.30 and a beta of 0.59. The business has a 50 day moving average of $133.17 and a 200 day moving average of $136.64.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Thursday, May 2nd. The biotechnology company reported ($2.48) EPS for the quarter, missing the consensus estimate of ($1.57) by ($0.91). Ascendis Pharma A/S had a negative net margin of 152.68% and a negative return on equity of 16,574.15%. The business had revenue of $103.11 million for the quarter, compared to analysts’ expectations of $85.72 million. On average, research analysts expect that Ascendis Pharma A/S will post -5.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. increased their target price on Ascendis Pharma A/S from $167.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. Wells Fargo & Company increased their target price on Ascendis Pharma A/S from $260.00 to $262.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $173.00 target price on shares of Ascendis Pharma A/S in a research report on Wednesday, May 15th. Morgan Stanley increased their target price on Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 16th. Finally, StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Thursday, May 23rd. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $179.44.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.